Use of zoledronic acid in the treatment of Paget's disease

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 913-918

  Seton, Margaret ^a   Krane, Stephen M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bisphosphonates; Paget's disease of bone; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; HYDROXYPROLINE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; AVASCULAR NECROSIS; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CALCIUM URINE LEVEL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOCAL GLOMERULOSCLEROSIS; FRACTURE; GASTROINTESTINAL IRRITATION; HEART ATRIUM FIBRILLATION; HUMAN; HYDROXYPROLINE URINE LEVEL; HYPERCALCEMIA; HYPOCALCEMIA; IRITIS; JAW DISEASE; KIDNEY DYSFUNCTION; NEPHROTOXICITY; OSTEOGENESIS IMPERFECTA; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; URINARY EXCRETION;

EID: 36448965672     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Adamson BB, Gallacher SJ, Byars J, et al. 1993. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet, 342:1459-60.
2. Amanat N, McDonald M, Godfrey C, et al. 2007. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res, 22:867-76.
3. Arden-Cordone M, Siris ES, Lyles KW, et al. 1997. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int, 60:415-8.
4. Bezzi M, Hasmim M, Bieler G, et al. 2003. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem, 278:43603-14.
5. Black DM, Delmas PD, Eastell R, et al. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 356:1809-22.
6. Body JJ. 1997. Clinical research update: zoledronate. Cancer, 80:1699-701.
7. Brown JP, Hosking DJ, Ste-Marie L, et al. 1999. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. Calcif Tissue Int, 64:93-9.
8. Buckler H, Fraser W, Hosking D, et al. 1999. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone, 24:81S-85S.
9. Chang JT, Green L, Beitz J. 2003. Renal failure with the use of zoledronic acid. N Engl J Med, 349:1676-9; discussion 1676-9.
10. Chung G, Keen RW. 2003. Zoledronate treatment in active Paget's disease. Ann Rheum Dis, 62:275-6.
11. Cooper C, Schafheutle K, Dennison E, et al. 1999. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res, 14:192-7.
12. Cundy T, Wattie D, Busch S, et al. 1999. Paget's disease in New Zealand: is it changing? Bone, 24:7S-9S.
13. Daubine F, Le Gall C, Gasser J, et al. 2007. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst, 99:322-30.
14. Demulder A, Takahashi S, Singer FR, et al. 1993. Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease. Endocrinology, 133:1979-92.
15. Derenne S, Amiot M, Barille S, et al. 1999. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP- 1 by the tumoral environment. J Bone Miner Res, 14:2048-56.
16. Dolgitser M, Stern L, Katz LM, et al. 2007. Manag Care Interface, 20:33-40.
17. Duran A, Serrano M, Leitges M, et al. 2004. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclasto-genesis. Dev Cell, 6:303-9.
18. Evans RA, Dunstan CR, Hills E, et al. 1983. Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone. Aust N Z J Med, 13:277-9.
19. Fleisch H. 2002. Development of bisphosphonates. Breast Cancer Res, 4:30-4.
20. Fournier P, Boissier S, Filleur S, et al. 2002. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res, 62:6538-44.
21. Gralow J, Tripathy D. 2007. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage, 33:462-72.
22. Green JR, Muller K, Jaeggi KA. 1994. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res, 9:745-51.
23. Green JR, Seltenmeyer Y, Jaeggi KA, et al. 1997. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol, 80:225-30.
24. Hocking LJ, Lucas GJ, Daroszewska A, et al. 2002. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet, 11:2735-9.
25. Hosking D, Lyles K, Brown JP, et al. 2007. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res, 22:142-9.
26. Hughes DE, Wright KR, Uy HL, et al. 1995. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 10:1478-87.
27. Khan SA, Brennan P, Newman J, et al. 1996. Paget's disease of bone and unvaccinated dogs. Bone, 19:47-50.
28. Krane SM. 1982. Etidronate disodium in the treatment of Paget's disease of bone. Ann Intern Med, 96:619-25.
29. Kukita A, Chenu C, McManus LM, et al. 1990. Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease. J Clin Invest, 85:1280-6.
30. Lipton A. 2007. The safety of zoledronic acid. Expert Opin Drug Saf, 6:305-13.
31. Macarol V, Fraunfelder FT. 1994. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol, 118:220-4.
32. Maerevoet M, Martin C, Duck L. 2005. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med, 353:99-102; discussion 99-102.
33. Markowitz, GS, Fine, PL, Stack, JI, et al. 2003. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int, 64:281-9.
34. Marten A, Lilienfeld-Toal M, Buchler MW, et al. 2007. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother, 30:370-7.
35. Marx RE. 2003. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg, 61:1115-7.
36. Marx RE, Sawatari Y, Fortin M, et al. 2005. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg, 63:1567-75.
37. McClung M, Recker R, Miller P, et al. 2007. Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone, 41:122-8.
38. Mee AP. 1999. Paramyxoviruses and Paget's disease: the affirmative view. Bone, 24:19S-21S.
39. Merigo E, Manfredi M, Meleti M, et al. 2005. Jaw one necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med, 34:613-7.
40. Miller PD, Brown JP, Siris ES, et al. 1999. A randomized, double-blind comparison of risedronate and etidronate in th treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med, 106:513-20.
41. Mills BG, Singer FR, Weiner LP, et al. 1980. Cell cultures from bone affected by Paget's disease. Arthritis Rheum, 23:1115-20.
42. Morales-Piga AA, Bachiller-Corral FJ, Abraira V, et al. 2002. Is clinical expressiveness of Paget's disease of bone decreasing? Bone, 30:399-403.
43. Odvina CV, Zerwekh JE, Rao DS, et al. 2005. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab, 90:1294-301.
44. Ott SM. 2004. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med, 351:190-2; author reply 190-2.
45. Ralston SH, Afzal MA, Helfrich MH, et al. 2007. Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone. J Bone Miner Res, 22:569-77.
46. Rebel A, Basle M, Pouplard A, et al. 198 1. Toward a viral etiology for Paget's disease of bone. Metab Bone Dis Relat Res, 3:235-8.
47. Reid IR, Brown JP, Burckhardt P, et al. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med, 346:653-61.
48. Reid IR, Miller P, Lyles K, et al. 2005. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med, 353:898-908.
49. Reid IR, Siris E. 1999. Alendronate in the treatment of Paget's disease of bone. Int J Clin Pract Suppl, 101:62-6.
50. Rendina D, Mossetti G, Viceconti R, et al. 2004. Risedronate and pamidronate treatment in the clinic management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int, 75:189-96.
51. Rima BK, Gassen U, Helfrich MH, et al. 2002. The pro and con of measles. virus in Paget's disease: con. J Bone Miner Res, 17:2; author reply 2293.
52. Rosen LS, Gordon D, Kaminski M. 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic Lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7:377-87.
53. Rosen CJ, Brown S. 2003. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med, 348:1503-4.
54. Siris E. Roodman GD. 2003. In Primer on the Metabolic Bone Diseases Favus MJ ed. Washington, DC: ASBMR, pp. 495-506.
55. Siris E, Weinstein RS, Altman R, et al. 1996. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab, 81:961-7.
56. Trombetti A, Arlot M, Thevenon J, et al. 1999. Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed, 66:467-76.
57. van Staa TP, Selby P, Leulkens HG, et al. 2002. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res, 17:465-71.
58. Whyte MP, Wenkert D, Clements KL, et al. 2003. Bisphosphonate-induced osteopetrosis. N Engl J Med, 349:457-63.
59. Widler L, Jaeggi KA, Glatt M, et al. 2002. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem, 45:3721-38.